Women’s Sexual Medicine Expert, Dr. Adrienne Lara, Joins Exclusive Haute Beauty Network

Dr. Adrienne Lara joins exclusive Haute Beauty Network as a Women’s Sexual Medicine expert representing the Los Angeles market.

OXNARD, Calif. (PRWEB) December 01, 2020

At Celebrating Women Center in Oxnard, California, Dr. Adrienne Lara, MD, wants her patients to know that she went to medical school for you. She believes good patient care is collaborative and involves both the patient and doctor working together as a team to get to the same goal — patient wellness. Dr. Lara takes the time to listen to her patients to better understand who they are, so she’s not treating symptoms, but the whole patient, including their mind, body, and spirit.

Voted favorite MedSpa by the Ventura County Reporter and Best Med Spa Readers’ Choice County Star 2018, Celebrating Women Center offers a number of health and wellness treatments focused on regenerative medicine that allows patients’ natural beauty to shine through, including micro-needling, platelet-rich plasma (PRP), and vaginal rejuvenation with advanced medical treatments such as laser therapy and surgical procedures.

After beginning her career in health care as a nurse, Dr. Lara then went to medical school at Boston University School of Medicine and completed her internship and residency program in obstetrics and gynecology at Beth Israel Deaconess Medical Center, which is part of Harvard Medical School.

Dr. Lara takes great pride in her community and believes as a doctor it’s her role to teach and share her knowledge so that her patients understand that they have options. Her integrity and authenticity when it comes to health care are why she’s so loved by all who see her.

Dr. Lara is fluent in English and Spanish to serve patients from a variety of backgrounds.

Learn more about Dr. Adrienne Lara by visiting: https://hauteliving.com/hautebeauty/member/dr-adrienne-lara/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

For the original version on PRWeb visit: https://www.prweb.com/releases/women_s_sexual_medicine_expert_dr_adrienne_lara_joins_exclusive_haute_beauty_network/prweb17528982.htm

Source Article

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors | News

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

Source Article

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

SOURCE Javelin Oncology

Related Links

https://javelinoncology.com/

Source Article

Read more

NSW fullback dilemma intensifies as Papenhuyzen joins Tedesco in Origin fitness race

Papenhuyzen, as well as Storm teammates Dale Finucane and Josh Addo-Carr, arrived at NSW’s Central Coast camp on Wednesday afternoon to undergo a series of medical examinations on the calf strain.

Melbourne’s grand final celebrations since Sunday night wouldn’t have provided Papenhuyzen much time to treat the injury, while the consumption of alcohol would have only hampered his recovery.

Blues teammates Jack Wighton, Clint Gutherson and Nathan Cleary watch on during last week's Dally M Medal ceremony.

Blues teammates Jack Wighton, Clint Gutherson and Nathan Cleary watch on during last week’s Dally M Medal ceremony.Credit:Grant Trouville/NRL Photos

Gutherson has predominantly been training at fullback for the Blues during training with Tedesco on restricted duties. The Roosters fullback has given himself until Saturday to make a decision.

The Blues are on Thursday expected to announce a 21-man squad for game one at Adelaide Oval next Wednesday, with Fittler still uncertain on the make-up of his best 17.

The fullback conundrum will go a long way to determining the back line, given Fittler had earmarked Gutherson to partner Jack Wighton in the centres, but the uncertainty around his first-choice fullbacks could see him bring in another debutant.

If Gutherson moves to fullback, St George Illawarra’s Zac Lomax and Penrith’s Stephen Crichton will do battle for the centre position expected to be vacated by the Eels captain’s shift.

Working in Lomax’s favour is the fact he is a specialist right centre, however he hasn’t played since the first weekend of September when the Dragons bowed out of the competition. Crichton is a left centre, however he has the added advantage of being in peak condition given the Panthers only finished up a few days ago after the grand final loss to Melbourne at ANZ Stadium.

The Blues are confident five-eighth Luke Keary will be fit to play despite adding Jarome Luai to the squad as extra cover at five-eighth on top of the inclusion of Walker.

Loading

Fittler also has to decide between Canberra’s Nick Cotric and the Roosters’ Daniel Tupou for the right wing spot. The front row rotation was also a topic of conversation at the Blues’ selection meeting on Wednesday with one of Junior Paulo, Payne Haas, Daniel Saifiti and Reagan Campbell-Gillard a chance of being left out of the side.

Queensland are expected to blood up to nine debutants for the opening game of the series, including AJ Brimson, Xavier Coates, Brenko Lee, Tino Faasuamaleaui, Mosese Fotuaika, Lindsay Collins, Jake Friend, Jaydn Su’A and Kurt Capewell.

Sport newsletter

Sports news, results and expert commentary delivered straight to your inbox each weekday. Sign up here.

Most Viewed in Sport

Loading

Source Article

Read more

Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne and Friends’ Virtual Concert Oct. 24

As part of its commitment to help educate Americans on the perils of Lyme disease, Quidel Corporation announced today that it will be one of the sponsors of the inaugural Global Lyme Alliance (GLA) “#FightLyme With Avril Lavigne & Friends” concert being held on Oct. 24. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia 2 Lyme FIA test.

“The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field, while expanding education and awareness programs for the general public and physicians. We’re honored to be their partner for this wonderful upcoming event.”

Being held in lieu of its annual gala, GLA will be presenting the inaugural #FightLyme With Avril & Friends virtual concert featuring Avril Lavigne, Rob Thomas, OneRepublic, Alessia Cara and host Wilmer Valderrama. The concert is designed to raise awareness and funds for GLA and The Avril Lavigne Foundation in support of their fight to conquer Lyme disease and other tick-borne diseases through research, education, awareness and patient services. Both Lavigne and Thomas have experienced Lyme disease on a personal level, and Lavigne is also a GLA board member who has been extremely vocal about the fight against Lyme disease.

The Oct. 24 concert will begin at 8 p.m. Eastern Time. Tickets can be purchased and more information is available at https://tinyurl.com/y54dn89a. More information on the Global Lyme Alliance can be found at GLA.org.

Lyme disease afflicts as many as 400,000 Americans every year and can lead to a number of serious, life-threatening problems if not caught early. Leading the way in Lyme disease testing is Quidel’s innovative Sofia® 2 Lyme FIA test. This test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. Given that the vast majority of patients tested are negative, not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative.

About Quidel Corporation

Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive

Read more

New dentist joins Sarrell Dental in Enterprise | News

Sarrell Dental of Enterprise is pleased to announce the addition of Dentist, Grant Ross, DMD, at its Enterprise location, 1100 Rucker Blvd Suite A1.

The addition of Dr. Ross allows the practice to expand its hours to five days a week and provide additional access to oral health care services in the Enterprise community.

Ross received his undergraduate from Mississippi College, a Master’s degree from the University of Mississippi Medical Center and attended dental school at Lake Erie College of Osteopathic Medicine in Bradenton, Florida.

Ross’ approach to dental care is driven by Sarrell Dental’s unique philosophy of Preventistry®. No one is born knowing how to care for his or her teeth, and if oral health professionals can intercede early, provide quality education and care then we can set patients up for a lifetime of good oral health and support full-body health.

“As a dentist at Sarrell Dental, I look forward to the rewarding work of providing quality oral health care to a community that has limited access. If we can educate our patients on preventive care and provide them with the care they need, we can truly change their dental experience and make a profound impact over a lifetime,” Ross said.

Ross and his wife, Courtney welcomed their son Benjamin to the world earlier this year. When he is not enjoying time with family, Ross spends his spare time fishing, running, playing disc golf and video games.

Source Article

Read more

Sidra Medicine joins hands with MoPH in ‘Are you ok’ campaign

Sidra Medicine, a Qatar Foundation entity, has partnered with the Ministry of Public Health (MoPH) in its national mental health and wellness campaign ‘Are you ok’ to highlight the support services available for women, children and young people in Qatar.

“The (coronavirus) pandemic has changed the landscape regarding the critical need for robust mental health support systems. It is very assuring and speaks of the calibre of the healthcare services in Qatar, to see how the Ministry of Public Health and Sidra Medicine have rapidly mobilised to keep mental health on top of the country’s service agenda,” Professor Muhammed Waqar Azeem, the chair of Psychiatry at Sidra Medicine said.

“At Sidra Medicine, we remain committed to supporting the people of Qatar, particularly children, young people and perinatal women in meeting their mental healthcare needs. In addition to world class mental health services, our Department of Psychiatry has started a number of educational and training programmes and is also involved in various leading-edge mental health-related research projects.”

Sidra Medicine offers Child and Adolescent Mental Health, Adolescent Medicine and Perinatal Mental Health services in Qatar. The services are either referral-based (in the case of children) or self-referral/ direct (perinatal mental health services).

Sidra Medicine’s Child and Adolescent Mental Health Service (CAMHS) is available for children aged 5 to 18 years and includes outpatient, inpatient, consultation liaison and emergency care.

The service can be accessed via referral from Primary Health Care Centres, private clinics, schools and other sources.

“As part of our ongoing efforts to strengthen mental health support services, we have focused on patient care, education to build local human resources, research and building community models of care in Qatar. The success of our programme is based on the collaboration of patients, their relatives and our staff, who all work to help achieve patient goals to live their lives as fully possible. I am also proud of our team’s achieving accreditation for the world’s first Child and Adolescent Psychiatry Fellowship from the Accreditation Council for Graduate Medical Education International (ACGMEI),” Dr Ahsan Nazeer, division chief of CAHMS at Sidra Medicine, said.

“Our advice to parents dealing with children with anxiety, especially during this time, is to encourage their children to share their concerns and have frank and open discussions about their fears and concerns. It is also important that children obtain accurate information from reliable sources. We also encourage parents to focus on instilling a sense of hope and optimism in their children by role modelling appropriate positive behaviuors,” Nazeer said.

Dr Alanoud al-Ansari, division chief of Adolescent Medicine whose clinic provides developmentally appropriate mental health and medical care for adolescents aged 12 to 18 years, has seen a rise in anxiety in teenagers.

“Teenagers are manifesting their anxiety around loss of control and unpredictability through eating disorders, depression and cutting themselves. Many of them have not been able to cope with being back at school. Despite families being in lockdown and opting to stay home during the pandemic, many families while

Read more

HFAP Joins ACHC

HFAP Joins ACHC

PR Newswire

CARY, N.C., Oct. 20, 2020

Combined Nonprofit Organization Meets Accreditation Needs of Healthcare Providers Across the Entire Continuum of Care

CARY, N.C., Oct. 20, 2020 /PRNewswire/ — In a historic move, Accreditation Commission for Health Care (ACHC) and Healthcare Facilities Accreditation Program (HFAP) are joining to form a single company with the programs, knowledge and resources to provide complete, quality accreditation and certification services to healthcare providers globally across the entire continuum of care. HFAP will operate as a brand within ACHC, and collectively the organization will be known as ACHC. 

Accreditation Commission for Health Care
Accreditation Commission for Health Care

Effective October 19, 2020, the merger of ACHC and AAHHS, HFAP’s parent company, which has been formally approved by the Centers for Medicare & Medicaid Services (CMS), drives innovation, streamlines services and creates new opportunities for existing customers and healthcare organizations of both previously separate, nonprofit organizations. It is the first time that two accrediting organizations with deeming authority from CMS have merged.

“The union between ACHC and HFAP makes perfect sense, from our reputable legacies and complementary cultures, to our shared dedication to providing unparalleled service to clients,” said José Domingos, President and CEO of ACHC. “Together, the combined services of ACHC and HFAP open possibilities for healthcare providers, affording them more choices and greater ease in meeting the accreditation and certification needs of their organizations.”

“HFAP is America’s original healthcare accreditation program and, since its founding in 1945, has driven advancements in patient safety and quality of care through a collaborative, informative and peer-based approach to the accreditation experience,” said Meg Gravesmill, CEO of AAHHS. “ACHC has a similar philosophy, and the expanded program choices, available resources and education opportunities under the merged company give our customers greater value and convenience in meeting their strategic business goals and broadening plans for the future.”

Full Suite of Accreditation and Certification Offerings
The merger  streamlines accreditation and certification services for healthcare providers with multiple survey needs. ACHC has CMS deeming authority for home health, hospice, renal dialysis, home infusion therapy, and DMEPOS. The newly expanded ACHC adds HFAP programs with CMS deeming authority for hospitals, ambulatory surgery centers, clinical laboratories and critical access hospitals.

Additional HFAP offerings—such as accreditation programs for ambulatory specialty care (office-based surgery), non-deemed accreditation and specialty certification for four levels of stroke care, laser and lithotripsy services, inpatient and outpatient joint replacement and wound care—will expand and complement the ACHC portfolio, which also includes programs for ambulatory care, behavioral health, pharmacy, private duty and sleep.

Seamless Transition for Existing Customers and Employees
This merger does not affect accreditation cycles for either ACHC or HFAP customers. Current accreditation and/or certification status, account managers and processes will not change. Furthermore, the merger does not require current HFAP customers to undergo an initial survey.

“Our merger brings existing HFAP customers additional opportunities to be awarded recognition of their programs and a broader range of education,” said Gravesmill. “As importantly, customers will continue to

Read more

UK lab joins global network to compare coronavirus vaccine candidates

LONDON (Reuters) – A second British laboratory is joining a global lab network to assess data from potential coronavirus vaccines, set up by a major non-profit health emergencies group to establish the effectiveness of different vaccine candidates.

Earlier this month, the Coalition for Epidemic Preparedness Innovations (CEPI) set up the network, allowing scientists and drugmakers to compare vaccines and speed up selection of the most effective shots.

Britain’s Medicines and Healthcare products Regulatory Agency said on Tuesday the National Institute for Biological Standards and Control (NIBSC) was joining the scheme, and had received funding from CEPI to develop an international standard for the COVID-19 antibody.

That means the NIBSC will produce a sample of antibody with a defined amount of biological activity that can be used by regulators and vaccine makers to calibrate their tests.

“This is an important initiative providing a service to vaccine developers globally and permits accurate evaluation of candidate vaccines for this pandemic,” Dr Mark Page, who is leading the work at NIBSC, said.

Public Health England is also involved in the CEPI scheme.

Hundreds of potential coronavirus vaccines are in various stages of development around the world, with shots developed in Russia and China already being deployed before full efficacy trials have been done, and front-runners from Pfizer <PFE.N>, Moderna <MRNA.O> and AstraZeneca <AZN.L> likely to have final-stage trial results before year-end.

CEPI itself is co-funding nine of the vaccines in development, including candidates from Moderna, AstraZeneca, Novavax <NVAX.O> and CureVac.

(Reporting by Alistair Smout; Editing by Mark Potter)

Source Article

Read more